統計學系

Medicine & Life Sciences

1. Neoplasms 96%
2. Survival 66%
3. Non-Small Cell Lung Carcinoma 58%
4. Genes 54%
5. Sample Size 51%
6. Datasets 49%
7. Therapeutics 42%
8. Biomarkers 42%
9. Lung Neoplasms 41%
10. Single Nucleotide Polymorphism 39%
11. Proteomics 39%
12. Clinical Trials 39%
13. Rheumatoid Arthritis 36%
14. Diffuse Scleroderma 36%
15. Data Analysis 33%
16. Proteins 32%
17. Mutation 32%
18. High-Throughput Nucleotide Sequencing 32%
19. Statistics 32%
20. Gene Expression 32%
21. Paclitaxel 31%
22. Radiotherapy 30%
23. Colorectal Neoplasms 30%
24. Population 29%
25. Exome 29%
26. Genome 28%
27. Drug Therapy 28%
28. Hepatocellular Carcinoma 27%
29. Lung 27%
30. Logistic Models 27%
31. Adenocarcinoma 25%
32. Cohort Studies 24%
33. Confidence Intervals 24%
34. Transcriptome 23%
35. Carcinoma 23%
36. Haplotypes 22%
37. Mortality 22%
38. Linear Models 22%
39. Randomized Controlled Trials 21%
40. Renal Dialysis 21%
41. ErbB Receptors 21%
42. Carcinogenesis 20%
43. Growth 20%
44. Systemic Scleroderma 20%
45. Odds Ratio 20%
46. Pharmaceutical Preparations 20%
47. Urinary Bladder Neoplasms 19%
48. Transitional Cell Carcinoma 19%
49. Triple Negative Breast Neoplasms 19%
50. Quality Control 19%
51. Rheumatology 19%
52. Genotype 19%
53. Penicillamine 18%
54. Costs and Cost Analysis 18%
55. Mass Spectrometry 18%
56. Transforming Growth Factors 18%
57. RNA-Seq 18%
58. Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry 17%
59. Head and Neck Neoplasms 17%
60. Skin 17%
61. Polyps 17%
62. Polycyclic Aromatic Hydrocarbons 17%
63. Adenoma 17%
64. Technology 16%
65. Joints 16%
66. Nonlinear Dynamics 16%
67. Statistical Models 16%
68. Schizophrenia 16%
69. Phenotype 16%
70. MicroRNAs 15%
71. Small Cell Lung Carcinoma 15%
72. Quality of Life 15%
73. Research Personnel 14%
74. Cluster Analysis 14%
75. Cell Line 13%
76. Longitudinal Studies 13%
77. Health 13%
78. Research Design 13%
79. Prospective Studies 13%
80. RNA 13%
81. Squamous Cell Carcinoma 13%
82. Atlases 13%
83. Nitriles 13%
84. Thorax 13%
85. Serum 13%
86. Kidney 13%
87. Meta-Analysis 13%
88. Smoking 13%
89. Survival Analysis 13%

Mathematics

1. Design 100%
2. Model 49%
3. Clinical Trials 47%
4. D-optimal Design 47%
5. Longitudinal Data 42%
6. Linear Mixed Model 38%
7. Simulation Study 34%
8. Multiple Objectives 33%
9. Gene 32%
10. Experiment 30%
11. Sample Size 29%
12. Performance 29%
13. Right-censored Data 29%
14. Dose-response 27%
15. Testing 27%
16. Drugs 26%
17. Polynomial Model 25%
18. Missing Values 24%
19. Regression Model 24%
20. Two-stage Design 22%
21. Methodology 22%
22. Heteroscedasticity 22%
23. Minimax 21%
24. Sample Size Calculation 20%
25. Estimator 19%
26. Heteroscedastic Model 19%
27. Bayesian Optimal Design 19%
28. Nonlinear Mixed Effects Model 19%
29. Bayesian Design 19%
30. Conditional Expectation 19%
31. Evaluate 19%
32. Modeling 19%
33. Demonstrate 18%
34. Random Effects 18%
35. Regression 18%
36. Mediation 17%
37. Mediator 17%
38. Efficacy 16%
39. Metaheuristics 16%
40. Nonlinear Model 16%
41. Observation 16%
42. Model-based Clustering 16%
43. Toxicity 16%
44. Skew 15%
45. Sequencing 15%
46. Simulation 15%
47. Prediction 15%
48. Gene Expression 15%
49. Multiple Comparisons 15%
50. Binary Response 15%
51. Strategy 14%
52. Scleroderma 14%
53. Proportion 14%
54. Bayesian Analysis 14%
55. Genome 14%
56. Maximum Likelihood Estimation 14%
57. Estimate 14%
58. Cancer 14%
59. Parameter Estimation 14%
60. Logistic Model 13%
61. Poisson Model 13%
62. Randomized Trial 13%
63. Equivalence Theorem 13%
64. Adaptive Design 13%
65. t-distribution 13%
66. Confidence interval 13%
67. Model Discrimination 13%
68. Clustered Data 13%
69. Kaplan-Meier 13%
70. Sample Size Determination 12%
71. Paired Data 12%
72. Relationships 12%
73. Linear Model 12%
74. Control Charts 12%
75. Poisson Regression 12%
76. Genomics 12%
77. Locally Optimal Design 12%
78. Linear Mixed Effects Model 12%
79. Statistics 12%
80. Cell 11%
81. Clustering 11%
82. Unknown 11%
83. Missing at Random 11%
84. Adaptive Sampling 11%
85. Robustness 11%
86. Treatment Effects 11%
87. Semidefinite Programming 11%
88. Finite Mixture 11%
89. Approximate Design 11%